Recruiting Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination NCT06733675 Conditions Drug-Drug Interaction (DDI), FDC, Healthy Volunteer, +2 more Locations ICON, Clinical Research Phase I Unit — Lenexa, Kansas, United States View Trial Details
Completed A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men NCT02138799 Conditions Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide Locations Parexel International GmbH — Berlin, Germany View Trial Details
Completed Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects NCT02169713 Conditions Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics Locations Parexel International GmbH — Berlin, Germany View Trial Details
Completed Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects NCT02127034 Conditions Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics Locations Parexel International GmbH — Berlin, Germany View Trial Details
Completed A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet NCT01943487 Conditions Drug-Drug Interaction (DDI), Healthy Subjects Locations SGS Aster — Paris, France View Trial Details
Completed A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects NCT02083627 Conditions Drug-Drug Interaction (DDI), Healthy Subjects, Intestinal Absorption, +2 more Locations Parexel GmbH — Berlin, Germany View Trial Details
Completed A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects NCT01797198 Conditions Drug-Drug Interaction (DDI), Healthy Subjects Locations PAREXEL Early Phase Clinical Unit — Harrow, United Kingdom View Trial Details
